Clinical Implications of a Targeted RNA-Sequencing Panel in the Detection of Gene Fusions in Solid Tumors

The detection of recurrent gene fusions can help confirm diagnoses in solid tumors, particularly when the morphology and staining are unusual or nonspecific, and can guide therapeutic decisions. Although fluorescence in situ hybridization and PCR are often used to identify fusions, the rearrangement must be suspected, with only a few prioritized probes run. We hypothesized that the Illumina TruSight RNA Fusion Panel, which detects fusions of 507 genes and their partners, would uncover fusions with greater sensitivity than other approaches, leading to changes in diagnosis, prognosis, or therapy.

Source: Journal of Molecular Diagnostics - September 21, 2021 Category: Pathology Authors: Lulu Sun, Samantha N. McNulty, Michael J. Evenson, Xiaopei Zhu, Joshua Robinson, Patrick R. Mann, Eric J. Duncavage, John D. Pfeifer Tags: Regular article Source Type: research